229 related articles for article (PubMed ID: 32872736)
1. Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea.
Seo J; Son M
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S114-S122. PubMed ID: 32872736
[TBL] [Abstract][Full Text] [Related]
2. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea.
Son M; Seo J; Yang S
Hypertension; 2020 Sep; 76(3):742-749. PubMed ID: 32654557
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
[TBL] [Abstract][Full Text] [Related]
4. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
5. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.
Loader J; Lampa E; Gustafsson S; Cars T; Sundström J
J Am Heart Assoc; 2021 Aug; 10(15):e021154. PubMed ID: 34320843
[TBL] [Abstract][Full Text] [Related]
7. Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea.
Park J; Lee SH; You SC; Kim J; Yang K
PLoS One; 2021; 16(3):e0248058. PubMed ID: 33705440
[TBL] [Abstract][Full Text] [Related]
8. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.
de Abajo FJ; Rodríguez-Martín S; Lerma V; Mejía-Abril G; Aguilar M; García-Luque A; Laredo L; Laosa O; Centeno-Soto GA; Ángeles Gálvez M; Puerro M; González-Rojano E; Pedraza L; de Pablo I; Abad-Santos F; Rodríguez-Mañas L; Gil M; Tobías A; Rodríguez-Miguel A; Rodríguez-Puyol D;
Lancet; 2020 May; 395(10238):1705-1714. PubMed ID: 32416785
[TBL] [Abstract][Full Text] [Related]
9. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
[TBL] [Abstract][Full Text] [Related]
10. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK;
J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045
[TBL] [Abstract][Full Text] [Related]
11. Use of Renin-Angiotensin-Aldosterone System Inhibitors and Severe COVID-19 Outcomes in Patients with Hypertension: A Nationwide Cohort Study.
Bae JH; Choi SK; Kim NH; Lee J; Kim SG
Diabetes Metab J; 2021 May; 45(3):430-438. PubMed ID: 33611884
[TBL] [Abstract][Full Text] [Related]
12. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
Tadic M; Cuspidi C
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
[No Abstract] [Full Text] [Related]
13. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
14. Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study.
Jung SY; Choi JC; You SH; Kim WY
Clin Infect Dis; 2020 Nov; 71(16):2121-2128. PubMed ID: 32442285
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
[TBL] [Abstract][Full Text] [Related]
16. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.
Vila-Corcoles A; Satue-Gracia E; Ochoa-Gondar O; Torrente-Fraga C; Gomez-Bertomeu F; Vila-Rovira A; Hospital-Guardiola I; de Diego-Cabanes C; Bejarano-Romero F; Rovira-Veciana D; Basora-Gallisa J
J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1379-1388. PubMed ID: 32710674
[TBL] [Abstract][Full Text] [Related]
17. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.
Bauer AZ; Gore R; Sama SR; Rosiello R; Garber L; Sundaresan D; McDonald A; Arruda P; Kriebel D
J Clin Hypertens (Greenwich); 2021 Jan; 23(1):21-27. PubMed ID: 33220171
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
19. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.
Akhabue E; Vu TT; Vaidya A; Michos ED; de Boer IH; Kestenbaum B; Allison M; Szklo M; Ouyang P; Yancy CW; Wolf M; Isakova T; Carnethon MR
Am J Hypertens; 2019 Jan; 32(1):18-25. PubMed ID: 30256890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]